Our data show that women with GDM supplemented with myoinositol at the dose of 4000 mg/day have better glycaemic control, evaluated by SMBG, have a lower insulin requirement when insulin is further added to the treatment and show low birth weight and low frequency of neonatal hypoglycaemic events compared to women not supplemented with myoinositol. This evidence concerns the gene INS and gestational diabetes.